Cargando…

Effects of a Fluorescent Myosin Light Chain Phosphatase Inhibitor on Prostate Cancer Cells

Myosin light chain phosphatase (MLCP) is an enzyme important to regulation of cell cycle and motility that is shown to be upregulated in aggressive prostate cancer cells and tissue. We developed a fluorescent small molecule inhibitor of MLCP using structure based design in recombinant protein phosph...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grindrod, Scott, Suy, Simeng, Fallen, Shannon, Eto, Masumi, Toretsky, Jeffrey, Brown, Milton L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Research Foundation 2011
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356144/ https://www.ncbi.nlm.nih.gov/pubmed/22655237 http://dx.doi.org/10.3389/fonc.2011.00027

Ejemplares similares

Reconstituted Human Myosin Light Chain Phosphatase Reveals Distinct Roles of Two Inhibitory Phosphorylation Sites of the Regulatory Subunit, MYPT1
por: Khasnis, Mukta, et al.
Publicado: (2014)

Myosin light chain kinase and myosin light chain phosphatase from Dictyostelium: effects of reversible phosphorylation on myosin structure and function
Publicado: (1987)

Diversity and plasticity in signaling pathways that regulate smooth muscle responsiveness: Paradigms and paradoxes for the myosin phosphatase, the master regulator of smooth muscle contraction
por: Eto, Masumi, et al.
Publicado: (2017)

Myosin light-chain phosphatase regulates basal actomyosin oscillations during morphogenesis
por: Valencia-Expósito, Andrea, et al.
Publicado: (2016)

Unfair competition governs the interaction of pCPI-17 with myosin phosphatase (PP1-MYPT1)
por: Filter, Joshua J, et al.
Publicado: (2017)

cGMP effects on vascular tone: modulating the activity of myosin light chain phosphatase
por: Brozovich, Frank V
Publicado: (2009)

Regulation of Myosin Light-Chain Phosphatase Activity to Generate Airway Smooth Muscle Hypercontractility
por: Álvarez-Santos, Mayra D., et al.
Publicado: (2020)

Myosin light chain phosphatase catalytic subunit dephosphorylates cardiac myosin via mechanisms dependent and independent of the MYPT regulatory subunits
por: Lee, Eunyoung, et al.
Publicado: (2022)

Bothersome Hematospermia Following Stereotactic Body Radiation Therapy for Prostate Cancer
por: Shah, Sarthak, et al.
Publicado: (2021)

Attenuated platelet aggregation in patients with septic shock is independent from the activity state of myosin light chain phosphorylation or a reduction in Rho kinase-dependent inhibition of myosin light chain phosphatase
por: Reddi, Benjamin AJ, et al.
Publicado: (2015)

Treatment Interruptions During Stereotactic Body Radiotherapy for Prostate Cancer
por: Pepin, Abigail N., et al.
Publicado: (2022)

Quantifying myosin light chain phosphorylation in single adherent cells with automated fluorescence microscopy
por: Bhadriraju, Kiran, et al.
Publicado: (2007)

Utilization of Patient-Reported Outcomes to Guide Symptom Management during Stereotactic Body Radiation Therapy for Clinically Localized Prostate Cancer
por: Danner, Malika, et al.
Publicado: (2017)

Prostate-Specific Antigen 5 Years following Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: An Ablative Procedure?
por: Kataria, Shaan, et al.
Publicado: (2017)

Dysuria Following Stereotactic Body Radiation Therapy for Prostate Cancer
por: Janowski, Einsley-Marie, et al.
Publicado: (2015)

Low Incidence of Fatigue after Hypofractionated Stereotactic Body Radiation Therapy for Localized Prostate Cancer
por: Dash, Chiranjeev, et al.
Publicado: (2012)

Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer in Men With a High Baseline International Prostate Symptom Score (IPSS ≥ 15)
por: Aghdam, Nima, et al.
Publicado: (2020)

TIMAP inhibits endothelial myosin light chain phosphatase by competing with MYPT1 for the catalytic protein phosphatase 1 subunit PP1cβ
por: Wang, Xin, et al.
Publicado: (2019)

Bleeding Risk Following Stereotactic Body Radiation Therapy for Localized Prostate Cancer in Men on Baseline Anticoagulant or Antiplatelet Therapy
por: Pepin, Abigail, et al.
Publicado: (2021)

Utilization of Iodinated SpaceOAR Vue™ During Robotic Prostate Stereotactic Body Radiation Therapy (SBRT) to Identify the Rectal–Prostate Interface and Spare the Rectum: A Case Report
por: Conroy, Dylan, et al.
Publicado: (2021)

Proctitis 1 Week after Stereotactic Body Radiation Therapy for Prostate Cancer: Implications for Clinical Trial Design
por: Paydar, Ima, et al.
Publicado: (2016)

Rationale for Stereotactic Body Radiation Therapy in Treating Patients with Oligometastatic Hormone-Naïve Prostate Cancer
por: Bhattasali, Onita, et al.
Publicado: (2013)

Self-Reported Burden in Elderly Patients With Localized Prostate Cancer Treated With Stereotactic Body Radiation Therapy (SBRT)
por: Aghdam, Nima, et al.
Publicado: (2020)

Cardiac myosin regulatory light chain kinase modulates cardiac contractility by phosphorylating both myosin regulatory light chain and troponin I
por: Sevrieva, Ivanka R., et al.
Publicado: (2020)

Association of the Myosin-binding Subunit of Myosin Phosphatase and Moesin: Dual Regulation of Moesin Phosphorylation by Rho-associated Kinase and Myosin Phosphatase
por: Fukata, Yuko, et al.
Publicado: (1998)

Urinary Morbidity in Men Treated With Stereotactic Body Radiation Therapy (SBRT) for Localized Prostate Cancer Following Transurethral Resection of the Prostate (TURP)
por: Pepin, Abigail, et al.
Publicado: (2020)

Urethrogram-Directed Stereotactic Body Radiation Therapy for Clinically Localized Prostate Cancer in Patients with Contraindications to Magnetic Resonance Imaging
por: Paydar, Ima, et al.
Publicado: (2015)

Ten-Year Single Institutional Analysis of Geographic and Demographic Characteristics of Patients Treated With Stereotactic Body Radiation Therapy for Localized Prostate Cancer
por: Aghdam, Nima, et al.
Publicado: (2021)

Effects of Myosin “Essential” Light Chain A1 on the Aggregation Properties of the Myosin Head
por: Markov, D.I., et al.
Publicado: (2010)

Phosphorylation of myosin regulatory light chain controls myosin head conformation in cardiac muscle
por: Kampourakis, Thomas, et al.
Publicado: (2015)

Improved Irritative Voiding Symptoms 3 Years after Stereotactic Body Radiation Therapy for Prostate Cancer
por: Rana, Zaker, et al.
Publicado: (2014)

Impact of Age on Patient-Reported Outcomes Following Stereotactic Body Radiation Therapy for Prostate Cancer
por: Pepin, Abigail, et al.
Publicado: (2021)

Association of baseline self-reported fatigue with overall survival after stereotactic body radiation therapy for localized prostate cancer
por: Simhal, Rishabh K., et al.
Publicado: (2022)

Thirteen is enough: the myosins of Dictyostelium discoideum and their light chains
por: Kollmar, Martin
Publicado: (2006)

Synthesis of myosin heavy and light chains in muscle cultures
Publicado: (1975)

Decreased Phosphatase Activity, Increased Ca(2+) Sensitivity, and Myosin Light Chain Phosphorylation in Urinary Bladder Smooth Muscle of Newborn Mice
por: Ekman, Mari, et al.
Publicado: (2005)

Diffusion of myosin light chain kinase on actin: A mechanism to enhance myosin phosphorylation rates in smooth muscle
por: Hong, Feng, et al.
Publicado: (2015)

Rationale for Utilization of Hydrogel Rectal Spacers in Dose Escalated SBRT for the Treatment of Unfavorable Risk Prostate Cancer
por: Repka, Michael C., et al.
Publicado: (2022)

Clinical Characteristics and Management of Late Urinary Symptom Flare Following Stereotactic Body Radiation Therapy for Prostate Cancer
por: Woo, Jennifer A., et al.
Publicado: (2014)

Restoration of Cardiac Myosin Light Chain Kinase Ameliorates Systolic Dysfunction by Reducing Superrelaxed Myosin
por: Hitsumoto, Tatsuro, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jpp5e06ba7ppkned33r91d5m87